Potassium citrate-sodium citrate-citric acid solution
Spl unclassified section
Potassium Citrate-Sodium Citrate-Citric Acid Solution
Potassium Citrate-Sodium Citrate-Citric Acid Solution is a stable and pleasant-tasting oral systemic alkalizer containing potassium citrate, sodium citrate, and citric acid in a sugar-free, non-alcoholic base.
Potassium Citrate-Sodium Citrate-Citric Acid Solution contains in each teaspoonful (5 mL):
Potassium Citrate Monohydrate ........ 550 mg
Sodium Citrate Dihydrate ................. 500 mg
Citric Acid Monohydrate .................. 334 mg
Each mL contains 1 mEq potassium ion and 1 mEq sodium ion and is equivalent to 2 mEq bicarbonate (HCO3)
propylene glycol, sorbitol, polyethylene glycol 400, sodium benzoate, sodium saccharin, FD&C yellow #6, raspberry flavor, and purified water.
Potassium Citrate Monohydrate has the chemical name: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate. Its chemical structure is as follows.
Sodium Citrate Dihydrate has the chemical name: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt, dihydrate. Its chemical structure is as follows.
Citric Acid Monohydrate has the chemical name:
1,2,3-Propanetricarboxylic acid, 2-hydroxy-, monohydrate. Its chemical structure is as follows.
Potassium citrate and sodium citrate are absorbed and metabolized to potassium bicarbonate and sodium bicarbonate, thus acting as systemic alkalizers. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of the citrates are excreted in the urine unchanged.
Indications and usage
Potassium Citrate-Sodium Citrate-Citric Acid Solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urine pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion.
Severe renal impairment with oliguria or azotemia, untreated Addisons disease, or severe myocardial damage. In certain situations, when patients are on a sodium-restricted diet, the use of potassium citrate may be preferable; or, when patients are on a potassium-restricted diet, the use of sodium citrate may be preferable.
Warnings and precautions
There have been several reports, published and unpublished, concerning nonspecific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of enteric-coated thiazides with potassium salts. These lesions may occur with enteric-coated potassium tablets alone or when they are used with nonenteric-coated thiazides, or certain other oral diuretics. These small-bowel lesions have caused obstruction, hemorrhage, and perforation. Surgery was frequently required and deaths have occurred. Based on a large survey of physicians and hospitals, both United States and foreign, the incidence of these lesions is low, and a causal relationship in man has not been definitely established. Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously. Therefore, coated potassium-containing formulations should be administered only when indicated, and should be discontinued immediately if abdominal pain, distention, nausea, vomiting, or gastrointestinal bleeding occur.
Do not exceed recommended dosage. Discontinue use if adverse reactions occur. Should be used with caution by patients with low urinary output or reduced glomerular filtration rates unless under the supervision of a physician. Aluminum-based antacids should be avoided in these patients. Patients should be directed to dilute adequately with water and, preferably, to take each dose after meals, to minimize the possibility of gastrointestinal injury associated with oral ingestion of potassium salt preparations and to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy.
Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity. Periodic examination and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.
Potassium Citrate-Sodium Citrate-Citric Acid Solution is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis, especially in the presence of hypocalcemia. Potassium intoxication causes listlessness, weakness, mental confusion, and tingling of extremities.
Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions. Overdosage with potassium salts may cause hyperkalemia and alkalosis, especially in the presence of renal disease.
Dosage and administration
Potassium Citrate-Sodium Citrate-Citric Acid Solution should be administrated by diluting with water, followed by additional water, if desired. Palatability is enhanced if chilled before taking.
Proper dilution may help prevent gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations.
Usual Adult Dosage: 3 to 6 teaspoonfuls (15 to 30 mL), diluted with water, four times a day, after meals and at bedtime, or as directed by a physician.
Usual Pediatric Dosage: 1 to 3 teaspoonfuls
(5 to 15 mL), diluted with water; four times a day, after meals and at bedtime, or as directed by a physician.
Usual Dosage Range: 2 to 3 teaspoonfuls
(10 to 15 mL), diluted with water, taken four times a day, will usually maintain a urinary pH of 6.5-7.4. 3 to 4 teaspoonfuls (15 to20 mL), diluted with water taken four times a day, will usually maintain a urinary pH of 7.0-7.6 throughout most of the 24 hours without unpleasant side effects. To check urine pH, HYDRION Paper (pH 6.0-8.0) or NITRAZINE Paper (pH 4.5-7.5) are available and easy to use.
SHAKE WELL BEFORE USING
Potassium Citrate-Sodium Citrate-Citric Acid Solution (orange colored, raspberry flavored) is supplied in the following oral dosage form: NDC 58657-411-16 (16 fl oz bottles).
Keep tightly closed. Store at controlled room temperature, 20-25 C (68-77 F). Protect from excessive heat and freezing.
Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing.
Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. IN CASE OF ACCIDENTAL OVERDOSAGE, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.
Method Pharmaceuticals, LLC
Arlington, TX 76006
Rev. Date: 10/2014
Ingredients and appearance - Product information
Potassium citrate-sodium citrate-citric acid solution- Potassium citrate, trisodium citrate dihydrate and citric acid monohydrate
|Product Type||HUMAN PRESCRIPTION DRUG LABEL||Item Code (Source)||NDC: 58657-311|
|Route of Administration||Oral|
|Potassium citrate ( UNII: EE90ONI6FF)( Anhydrous citric acid - UNII: XF417D3PSL )||550 mgin 5 mL|
|Trisodium citrate dihydrate ( UNII: B22547B95K)( Anhydrous citric acid - UNII: XF417D3PSL )||500 mgin 5 mL|
|Citric acid monohydrate ( UNII: 2968PHW8QP)( Anhydrous citric acid - UNII: XF417D3PSL )||334 mgin 5 mL|
|Potassium cation||( UNII: 295O53K152)|
|Sodium cation||( UNII: LYR4M0NH37)|
|Propylene glycol||( UNII: 6DC9Q167V3)|
|Sorbitol||( UNII: 506T60A25R)|
|Polyethylene glycol 400||( UNII: B697894SGQ)|
|Sodium benzoate||( UNII: OJ245FE5EU)|
|Saccharin sodium||( UNII: SB8ZUX40TY)|
|Fd&c yellow no. 6||( UNII: H77VEI93A8)|
|Water||( UNII: 059QF0KO0R)|
|Marketing Category||Application Number or Monograph Citation||Territorial Authority||Marketing Start Date|
|unapproved drug other||USA|
Labeler - Method Pharmaceuticals, LLC( 060216698)
Principal display panel
Citric Acid Solution
55 0 mg/ 500 mg/ 334 mg per 5 mL
SHAKE WELL BEFORE USE
16 fl oz (473 mL )